Roche has moved a step closer to expanding the use of its immunotherapy Tecentriq® (atezolizumab) in early-stage colon cancer after the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for the treatment.
The application seeks approval for adjuvant Tecentriq and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs), in combination with chemotherapy, for patients with stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer. These tumors are characterized by high mutation rates and are often more responsive to immunotherapy.
The FDA is expected to make a decision on the application by October 9, 2026. If approved, the regimen could become the first immunotherapy-based adjuvant treatment option for patients with resected stage III dMMR/MSI-H colon cancer, potentially redefining the standard of care for this subgroup of patients.
The filing is supported by results from the landmark Phase III ATOMIC study, which was recently published in the *New England Journal of Medicine*. The trial demonstrated that adding Tecentriq to standard FOLFOX6 chemotherapy significantly improved outcomes compared with chemotherapy alone.
According to the study, the combination reduced the risk of disease recurrence or death by 50% in patients with stage III dMMR colon cancer. The trial also showed a notable improvement in disease-free survival. At 36 months, 86% of patients treated with Tecentriq plus FOLFOX6 remained disease-free, compared with 76% of those who received chemotherapy alone.
The safety profile of the combination was consistent with previous studies involving Tecentriq and FOLFOX6, with no unexpected safety concerns reported.
Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said the FDA’s acceptance of the filing represents an important milestone in advancing treatment options for patients with early-stage colon cancer. He noted that the ATOMIC study demonstrated the potential of Tecentriq combined with chemotherapy to significantly reduce the likelihood of recurrence and help more patients remain cancer-free after surgery.
The need for improved adjuvant therapies remains substantial. Colon cancer is among the most frequently diagnosed cancers worldwide and remains one of the leading causes of cancer-related deaths. More than one million people are diagnosed globally each year. Despite advances in surgery and chemotherapy, approximately 30% of patients with stage III disease experience recurrence within five years.
Patients with dMMR/MSI-H tumors account for roughly 15% of all colon cancer cases. These tumors possess genetic characteristics that make them particularly suitable candidates for immunotherapy, creating an opportunity for more personalized treatment approaches.
Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, emphasized the significance of the regulatory milestone, stating that one in three patients with stage III colon cancer will relapse within five years. He described the filing as a step toward more individualized treatment strategies based on tumor biology, potentially improving long-term outcomes for patients.
Roche is also pursuing regulatory submissions outside the United States, including filings with the European Medicines Agency, as it seeks to make the therapy available globally.
The ATOMIC study was sponsored by the U.S. National Cancer Institute and conducted by the Alliance for Clinical Trials in Oncology in collaboration with Roche and Germany’s Arbeitsgemeinschaft Internistische Onkologie (AIO). The partnership reflects ongoing efforts between industry and academic research groups to develop more effective treatments for challenging cancers.
If approved, Tecentriq could become a pioneering immunotherapy option in the adjuvant setting for dMMR/MSI-H colon cancer, offering new hope for reducing recurrence and improving long-term survival following surgery.